Scott Greenspahn
Hospitalist · Burien, WANPI 1265665293
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Orexo US, Inc. at 32.1% of the total. Among hospitalist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Orexo US, Inc.$410
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$201
- Lilly USA, LLC$86
- Amarin Pharma, Inc.$74
- Novartis$50
- Amgen$47
- plus $410 from 19 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$1,278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Orexo US, Inc. | 26 | $410 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $201 |
| Lilly USA, LLC | 4 | $86 |
| Amarin Pharma, Inc. | 5 | $74 |
| Novartis | 2 | $50 |
| Amgen | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Novo Nordisk | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Corium, LLC | 1 | $19 |
| GSK | 1 | $18 |
| Bausch Health US, LLC | 1 | $18 |
| Braeburn Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Indivior Inc. | 3 | $15 |
| Linus Health, Inc. | 2 | $14 |
| Boston Scientific | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Neurelis, Inc. | 1 | $13 |
| Qiagen, LLC | 1 | $12 |
How this compares
$1,278 in reported general payments places this provider in the 95th percentile of 661 hospitalist providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 17 | $10,516 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $2,918 |
| Bupropion XlBupropion Hcl | 13 | $523 |
| Losartan Potassium | 29 | $461 |
| Atorvastatin Calcium | 34 | $370 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $279 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $276 |
| Rosuvastatin Calcium | 19 | $200 |
| Levothyroxine Sodium | 14 | $174 |
| Amlodipine Besylate | 14 | $122 |
| Trazodone Hcl | 12 | $98 |
| Lisinopril | 13 | $56 |
| Lamotrigine | 11 | $3 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Burien
- Niharika ChimalakondaBurien$292
- Ruth ArumalaRenton$13K
- James BarnesSeattle$12K
- Usman NaseerSeattle$8K
- Ziad Al Soufi Al SukkaryKirkland$4K
- Bryce JohnsonSeattle$4K
- Shelby ApodacaSpokane$3K
- Benjamin WolpawSeattle$3K
- Afshin BidariBellevue$2K
- Tanesh SadaranganiTacoma$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.